Germline RAD51C and RAD51D Mutations in High-Risk Chinese Breast and/or Ovarian Cancer Patients and Families.

Autor:	Kwong A; Division of Breast Surgery, Department of Surgery, The University of Hong Kong, Hong Kong SAR, China.; Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong SAR, China.; Cancer Genetics Centre, Breast Surgery Centre, Surgery Centre, Hong Kong Sanatorium & Hospital, Hong Kong SAR, China., Ho CYS; Division of Molecular Pathology, Department of Pathology, Hong Kong Sanatorium & Hospital, Hong Kong SAR, China., Au CH; Division of Molecular Pathology, Department of Pathology, Hong Kong Sanatorium & Hospital, Hong Kong SAR, China., Tey SK; Division of Breast Surgery, Department of Surgery, The University of Hong Kong, Hong Kong SAR, China., Ma ESK; Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong SAR, China.; Division of Molecular Pathology, Department of Pathology, Hong Kong Sanatorium & Hospital, Hong Kong SAR, China.
Jazyk:	angličtina
Zdroj:	Journal of personalized medicine [J Pers Med] 2024 Aug 16; Vol. 14 (8). Date of Electronic Publication: 2024 Aug 16.
DOI:	10.3390/jpm14080866
Abstrakt:	Background: RAD51C and RAD51D are crucial in homologous recombination (HR) DNA repair. The prevalence of the RAD51C and RAD51D mutations in breast cancer varies across ethnic groups. Associations of RAD51C and RAD51D germline pathogenic variants (GPVs) with breast and ovarian cancer predisposition have been recently reported and are of interest. Methods: We performed multi-gene panel sequencing to study the prevalence of RAD51C and RAD51D germline mutations among 3728 patients with hereditary breast and/or ovarian cancer (HBOC). Results: We identified 18 pathogenic RAD51C and RAD51D mutation carriers, with a mutation frequency of 0.13% (5/3728) and 0.35% (13/3728), respectively. The most common recurrent mutation was RAD51D c.270_271dupTA; p.(Lys91Ilefs*13), with a mutation frequency of 0.30% (11/3728), which was also commonly identified in Asians. Only four out of six cases (66.7%) of this common mutation tested positive for homologous recombination deficiency (HRD). Conclusions: Taking the family studies in our registry and tumor molecular pathology together, we concluded that this relatively common RAD51D variant showed incomplete penetrance in our local Chinese community. Personalized genetic counseling emphasizing family history for families with this variant, as suggested at the UK Cancer Genetics Group (UKCGG) Consensus meeting, would also be appropriate in Chinese families.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu